dalcelli + exemestane + goserelin

Dalcelli + exemestane + goserelin is a three-drug combination therapy under investigation primarily for hormone receptor-positive, HER2-negative breast cancer in premenopausal women. Dalcelli is an investigational agent; its precise mechanism and chemical class are not detailed in available sources, but it is being studied as part of neoadjuvant endocrine therapy regimens. Exemestane is a steroidal aromatase inhibitor that irreversibly inhibits estrogen synthesis by blocking the aromatase enzyme, thereby reducing estrogen levels and limiting growth stimulation of hormone-sensitive breast cancer cells[10]. Goserelin is a luteinizing hormone-releasing hormone (LHRH) agonist that suppresses ovarian function and reduces circulating estrogen by downregulating pituitary gonadotropins[5][8]. The rationale for combining these agents is to achieve profound estrogen suppression through both ovarian suppression (goserelin) and peripheral aromatization blockade (exemestane), with Dalcelli potentially providing additional antitumor activity. This regimen has been evaluated in phase II clinical trials as neoadjuvant or preoperative treatment for locally advanced or metastatic breast cancer[2][3].